Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,233 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Clear all

Conditions: Kidney Transplant Recipient
Interventions: Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication; Biological · Other
Lead sponsor: Mark Stegall; Other
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Post COVID-19 Condition, Long COVID
Interventions: Rintatolimod, Placebo / Normal Saline; Drug · Other
Lead sponsor: AIM ImmunoTech Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Canoga Park, California • Inglewood, California • San Diego, California + 2 more

Conditions: COVID-19, Sleep Apnea
Interventions: Continuous positive airway pressure; Device
Lead sponsor: Venkatesh Krishnamurthy; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Interventions: RSLV-132, Sodium Chloride 0.9%; Drug
Lead sponsor: Resolve Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Mobile, Alabama • Coral Gables, Florida • Pompano Beach, Florida + 2 more

Conditions: COVID-19, Diabete Mellitus
Interventions: Measure of physiologic parameters; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: COVID-19 SARS-CoV-2 Infection
Interventions: ibuzatrelvir, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 2,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 87
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 64 more

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: Covid19
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: COVID-19
Interventions: casirivimab+imdevimab combination therapy; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 10,078 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 102
States / cities: Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 71 more

Conditions: COVID19
Interventions: Diagnostic Software as Medical Device; Diagnostic Test
Lead sponsor: AudibleHealth AI, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: SARS-CoV-2 Infection, COVID19
Interventions: BNT162b2; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 2 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Jefferson, Louisiana • Kenner, Louisiana • New Orleans, Louisiana + 4 more

Conditions: Long COVID
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: RNA Virus Infections
Interventions: RT-PCR; Diagnostic Test
Lead sponsor: Ambry Genetics; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aliso Viejo, California

Conditions: Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
Interventions: TD-0903, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Duarte, California • Denver, Colorado • Sebring, Florida + 9 more

Conditions: Long Covid
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post-Acute COVID-19, Post COVID-19 Condition, Post Viral Fatigue, Dyspnea
Interventions: Computed Tomography of the Chest; Diagnostic Test
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Long COVID, Long Covid19, Dyspnea, Orthostasis, Cognitive Impairment
Interventions: Comprehensive Rehabilitation, Augmented Usual Care; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Covid19
Interventions: Not listed
Lead sponsor: Tulane University; Other
Eligibility: 6 Months to 120 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: COVID-19
Interventions: Duvelisib, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Ease Of Access To Covid Vaccine
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 15 Years to 17 Years
Enrollment: 454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tachycardia, Dyspnea, COVID-19
Interventions: Metoprolol Succinate; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 40 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: SARS-CoV-2
Interventions: DUR-928, Placebo; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: COVID-19
Interventions: VIR-7831, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 74
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more

Conditions: COVID 19, Coronavirus
Interventions: Fluvoxamine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Belleville, Illinois • St Louis, Missouri

Search by objective public record fields.

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

CPAP Efficacy in Post-COVID-19 Patients With Sleep Apnea

Phase 2 Study of RSLV-132 in Subjects With Long COVID

Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

ACTIV-2: A Study for Outpatients With COVID-19

A Wearable, Battery-free Screening System for SARS-CoV-2, the Virus Causing COVID-19 Infection

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

The Long COVID Treatment Trial

COVID-19 and SARS-CoV-2 Detection in Saliva

TD-0903 for ALI Associated With COVID-19

Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER)

Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection

Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial

Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)

Adolescents Seeking COVID Vaccination (Teen COVID Vax)

Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection